Showing 120 of 120on this page. Filters & sort apply to loaded results; URL updates for sharing.120 of 120 on this page
Anticipated Timelines PNT2002 (Prostate Cancer) PNT2003 (SSRT+ non-GEP ...
Lutetium-177 PNT2002 for Prostate Cancer | Open Medscience
PNT2002 / POINT Biopharma, Lantheus
ESMO 2024: Efficacy of 177Lu-PNT2002 in PSMA-Positive mCRPC Following ...
Frontiers | Initial clinical experience with [177Lu]Lu-PNT2002 ...
New therapy delays progression of recurrent prostate cancer | UCLA Health
PSMA-Targeting Radioligand Therapy in Prostate Cancer | Published in ...
Prostate Cancer Molecular Imaging and Therapy in MIRROR and 177Lu ...
Study on Treating Metastatic Castration-Resistant Prostate Cancer with ...
[225Ac]Ac-SibuDAB for Targeted Alpha Therapy of Prostate Cancer ...
ASCO 2021: Study Evaluating Metastatic Castrate Resistant Prostate ...
[Lu-177]-PNT2002 for Prostate Cancer Clinical Trial 2023 | Power
ESMO 2024 Quick Take Insights: Prostate Cancer
Adding 177Lu-PNT2002 to SBRT Improves PFS in Oligorecurrent Prostate ...
ESMO 22: Results of the 177Lu-PNT2002 SPLASH Trial | GU Oncology Now
FDA Fast Tracks 177Lu-PNT2002 for the Treatment of mCRPC
ESMO 2022: Efficacy and Safety of 177Lu-PNT2002 Prostate-Specific ...
SPLASH: 177Lu-PNT2002 achieves phase 3 outcomes for mCRPC | Urology Times
Lutetium-177 Prostate-Specific Membrane Antigen Therapy: A Practical ...
1400P Efficacy and safety of 177Lu-PNT2002 prostate-specific membrane ...
177Lu–Prostate-specific Membrane Antigen Radioligand Therapy in ...
177Lu-PNT2002 Significantly Improves rPFS Vs ARPI in Metastatic ...
177Lu-PNT2002 Received FDA Fast Track Designation for Metastatic CRPC
FDA Fast Tracks 177Lu-PNT2002 for the Treatment of mCRPC | Targeted ...
SPLASH: 177Lu-PNT2002 achieves phase 3 outcomes for mCRPC
Radioligand Therapy (RLT) Market by Product (Lutetium-177 Vipivotide ...
Dose‐adapted stereotactic body radiation therapy based on the response ...
ESMO 2024: Scientific Congress Highlights: Genitourinary Tumors, Prostate
Abstract PO-077: Study evaluating metastatic castrate resistant ...
Emerging PSMA Radioligand Therapy Shows Benefits for Metastatic ...
Navigating Therapeutic Choices in Prostate Cancer: Effective Decision ...
PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard ...
A Single Dose of Novel PSMA-Targeting Radiopharmaceutical Agent [177Lu ...
Lantheus and POINT Biopharma Announce FDA Grants Fast Track Designation ...
177Lu-PNT2002 Meets Primary Endpoint in Phase III mCRPC Trial ...
ESMO 2025: 177Lutetium-PSMA Therapy Neoadjuvant to Stereotactic ...
slide16
ASCO 2023: LuPARP: Phase 1 Trial of 177Lu-PSMA-617 and Olaparib in ...
Prostate-Specific Membrane Antigen Radioligand Therapy Using 177Lu-PSMA ...
177Lu-Prostate-Specific Membrane Antigen Neoadjuvant to Stereotactic ...
去势抵抗性前列腺癌最新疗法：177Lu-PNT2002有效降低死亡风险|癌症|医疗|患者_新浪新闻
Clinical Trials in Progress - Focus on Advanced Prostate Cancer
slide15
Lantheus' 177Lu-PNT2002 Shows Promise in mCRPC Treatment: Phase 3 ...
Optimized Therapeutic 177Lu-Labeled PSMA-Targeted Ligands with Improved ...
Lutetium Lu 177 Dotatate Radioequivalent Receives Tentative FDA ...
Synthesis and Preclinical Evaluation of 177Lu-Labeled Radiohybrid PSMA ...
POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company on ...
Chemical structures of selected prostate-targeting radionuclide therapy ...
Frontiers | 177Lu-labeled PSMA targeting therapeutic with optimized ...
The contemporary management of prostate cancer - Chakrabarti - CA: A ...
The efficacy benefits of radioisotopes in metastatic castration ...
:%0A%0A[Lu-177]-PNT2002%20for%20Prostate%20Cancer.png?md=1)
